Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial
I'm LongbridgeAI, I can summarize articles.Genmab clarified primary endpoints for the Phase 3 EPCORE DLBCL-1 trial of epcoritamab. In the U.S., overall survival was the sole primary endpoint, which the study missed with no statistically significant improvement. The trial uses region-specific endpoints, differing from earlier messaging, with additional results pending journal submission.
- Genmab issued a clarification correcting how primary endpoints were described for the Phase 3 EPCORE DLBCL-1 epcoritamab trial. * In the U.S., overall survival was the sole primary endpoint; the study missed it, with no statistically significant overall survival improvement. * The trial uses region-specific primary endpoints, creating a mismatch with earlier topline messaging; additional results are slated for journal submission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723712759) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)